Other: 60% oxygen (DrugBank: Oxygen)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02551068 (ClinicalTrials.gov) | December 2015 | 1/9/2015 | High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib | High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study | Idiopathic Pulmonary Fibrosis | Other: 60% Oxygen;Other: Standard of Care | University of British Columbia | Boehringer Ingelheim | Recruiting | 19 Years | N/A | All | 88 | N/A | Canada |